Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07015242 | A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma | PHASE2 | RECRUITING | 65 | — | — | Nov 6, 2025 | Dec 10, 2028 | Mar 24, 2026 | 82 | United States, France +1 |
Defined as the time from the date of liso-cel infusion to the date of first documented disease relapse or progression as assessed by the investigator, or death from any cause, whichever occurs first
| Arm | Type | Description |
|---|---|---|
| Liso-cel Administration | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Rituximab | DRUG | Specified dose on specified days |
| Methotrexate | DRUG | Specified dose on specified days |
| Procarbazine | DRUG | Specified dose on specified days |
| Temozolomide | DRUG | Specified dose on specified days |
| Liso-cel | BIOLOGICAL | Specified dose on specified days |
| Fludarabine | DRUG | Specified dose on specified days |
| Cyclophosphamide | DRUG | Specified dose on specified days |
| Calcium folinate | DRUG | Specified dose on specified days |
Inclusion Criteria * Participant must be 18 years or older at the time of signing the informed consent form (ICF). * Histologically confirmed primary central nervous system (CNS) lymphoma (PCNSL) prior to screening, as assessed by local pathology. * Transplant-ineligible based on physician's assess...